Fispemifene

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H27ClO3
Molecular Weight	422.944
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCCOCCOC1=CC=C(C=C1)C(=C(\CCCl)C2=CC=CC=C2)\C3=CC=CC=C3

InChI

InChIKey=NKZTZAQIKKGTDB-QPLCGJKRSA-N

InChI=1S/C26H27ClO3/c27-16-15-25(21-7-3-1-4-8-21)26(22-9-5-2-6-10-22)23-11-13-24(14-12-23)30-20-19-29-18-17-28/h1-14,28H,15-20H2/b26-25-

HIDE SMILES / InChI

Molecular Formula	C26H27ClO3
Molecular Weight	422.944
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18583549 | http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=112113 | http://adisinsight.springer.com/drugs/800013715

Fispemifene acts via estrogen receptors and has tissue-selective estrogenic and/or antiestrogenic effects – it has antagonist activity in breast tissue and acts as an estrogen agonist in bone. Due to its low estrogenicity in male rats, it might also be applicable for men. Fispemifene exhibits both antiestrogenic and anti-inflammatory action in the prostate. It could be considered as a new therapeutic option in the treatment and prevention of prostatic inflammation. Fispemifene had been in phase II clinical trials for the oral treatment of hypogonadism.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estrogen receptor alpha 127 Target ID: CHEMBL206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15501580 \| http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=112113	Antagonist 2778
Estrogen receptor beta 110 Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15501580	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypogonadism 28 Sources: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=112113 https://clinicaltrials.gov/ct2/show/NCT00415571 http://www.pharmacodia.com/yaodu/html/v1/chemicals/94c8e4495d11846b18dd44998eed4968.html	Primary		Phase II 1132	Unknown Approved Use Unknown
Prostatitis 25 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18583549	Primary		Preclinical	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
Compound Cloud	9954033
MuseChem	R034309	https://www.musechem.com/product/R034309.html
eMolecules	194970038	https://orderbb.emolecules.com/search/#?query=194970038

PubMed

Title	Date	PubMed
Selective estrogen receptor modulators prevent neointima formation after vascular injury.	2004 Nov 30	15501580
Fispemifene [Z-2-{2-[4-(4-chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis.	2008 Oct	18583549

Patents

Sample Use Guides

In Vivo Use Guide

300 mg once daily for 4 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:38:54 GMT 2023` Edited by `admin` on `Fri Dec 15 15:38:54 GMT 2023`
Record UNII	3VZ2833V08
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Fispemifene

Official Name

English

HM-101

Code

English

fispemifene [INN]

Common Name

English

2-[2-[4-[(1Z)-4-Chloro-1,2-diphenylbut-1-enyl]phenoxy]ethoxy]ethanol

Systematic Name

English

Ethanol, 2-[2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]ethoxy]-

Systematic Name

English

FISPEMIFENE [USAN]

Common Name

English

HM-101A

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C481